B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study

Triple-negative breast cancer has no specific treatment and unfavorable prognosis. Eribulin is one of the drugs widely used in this cohort of patients. In addition to its antimitotic effect, eribulin has an immunomodulant effect on the tumor microenvironment. In this study, we discover immunological...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashireva, Liubov A., Popova, Nataliya O., Kalinchuk, Anna Yu., Goldberg, Viktor E., Kovalenko, Elena I., Artamonova, Elena V., Manikhas, Aleksey G., Ponomarenko, Dmitriy M., Levchenko, Nataliya V., Rossokha, Elena I., Krasilnikova, Svetlana Yu., Zafirova, Marina A., Choynzonov, Evgeniy L., Perelmuter, Vladimir M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260581/
https://www.ncbi.nlm.nih.gov/pubmed/35814376
http://dx.doi.org/10.3389/fonc.2022.909505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260581/
https://www.ncbi.nlm.nih.gov/pubmed/35814376
http://dx.doi.org/10.3389/fonc.2022.909505

Ejemplares similares